PIN1 and Marinesco-Sjogren syndrome: Consistent with our hypothesis, the Pin1 inhibitor + aPD-1 group exhibited the slowest tumor growth and the smallest tumor volume, indicating Pin1 blockade enhances immunotherapy efficacy in MSS models.